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Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that is char-
acterized by abnormal communication between the arteries and veins in the skin,
mucosa, and various organs. HHT has been reported to show significant pheno-
typic variability and genetic heterogeneity with wide ethnic and geographic varia-
tions. Although mutations in the endoglin (ENG) and activin A receptor type II-like
1 (ACVRL1) genes have been known to cause HHT for more than 10 yr, little is known
about the clinical features or genetic background of Korean patients with HHT. In
addition, mutations in mothers against decapentaplegic homolog 4 (SMAD4) are
also seen in patients with the combined syndrome of juvenile polyposis and HHT.
This study examined five Korean patients with the typical manifestations of HHT
such as frequent epistaxis and pulmonary arteriovenous malformations. Direct
sequencing of the ENG and ACVRL1 genes revealed one known mutation, ENG
c.277C>T, in one patient and two novel mutations, ENG c.992-1G>C and ACVRL1
c.81dupT in two patients, respectively. The remaining two patients with negative
results were screened for SMAD4 mutations as well as gross deletions of ENG
and ACVRL1 using multiple ligation-dependent probe amplification, but none was
detected. Despite the small number of patients investigated, we firstly report Kore-
an patients with genetically confirmed HHT, and show the genetic and allelic het-
erogeneity underlying HHT.
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INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT), which is
also known as Rendu-Osler-Weber disease, is an autosomal
dominantly inherited disorder that is characterized by abnor-
mal communications between the arteries and veins (telang-
iectasia) in the skin, mucosa, and various organs (1). The preva-
lence of this disorder is estimated to be -1:1,300 to -1:
40,000 with some geographical variations (2-9). The clinical
features of HHT include spontaneous recurrent epistaxis,
mucocutaneous telangiectases (particularly on the tongue,
lips, oral cavity, fingers and nose), and arteriovenous malfor-
mations (AVM) in the pulmonary, cerebral, hepatic, gas-
trointestinal or spinal vessels (10).
HHT is genetically heterogeneous and can be subdivided
into HHT-1 and HHT-2 according to mutations in the en-
doglin (ENG) gene and the activin A receptor type II-like 1
(ACVRL1) gene, respectively (11, 12). These two subtypes
are clinically indistinguishable and share many phenotypes.
However, there appears to be some differences in the frequen-
cy of some their clinical manifestations. Pulmonary AVMs are
believed to be more common in patients with HHT-1 than
in HHT-2 (7, 13-17). Families with HHT-2 generally tend
to show a later onset of the symptoms and a milder phenotype.
The vast majority (-80%) of the ENG mutations in HHT-1
patients lead to premature stop codons and truncated peptides,
with no apparent hot focus. On the other hand, more than
half (-53%) of the mutations identified in ACVRL1 are mis-
sense substitutions, and the majorities of those mutations are
located in exons 8, 7, and 3. Some large deletions and inser-
tions as well as some splice site mutations in these two genes
have also been reported (2, 13, 18). Recently, other loci for
HHT, HHT-3, and HHT-4, were identified by linkage anal-
ysis (19, 20). Moreover, there are diseases presenting overlap-
ping features with HHT such as the Juvenile polyposis/hered-
itary hemorrhagic telangiectasia syndrome (JPHT) which is
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Accepted : 22 May 2008caused by the mutations in the mothers against decapentaplegic
homolog 4 (SMAD4) tumor suppressor gene (21). 
HHT is considered to be more common than previously
believed. However, there are no data on Korean patients with
genetically confirmed HHT. Therefore, this study examined
the clinical and genetic information of five Korean patients
with the typical manifestations of HHT.
MATERIALS AND METHODS
Subjects
A clinical investigation and genetic analysis was performed
in five Korean patients diagnosed with HHT according to
the criteria suggested by Shovlin et al. (10). The frequency
of epistaxis was graded according to the category suggested
by Bergler et al. (22): grade 1, less than once per week; grade
2, a few times per week; grade 3, more than once per day.
DNA sequence analysis
After obtaining informed consent, the genomic DNA was
isolated from the peripheral blood leukocytes using a Wiz-
ard Genomic DNA Purification kit according to the manu-
facturer’s instructions (Promega, Madison, WI, U.S.A.). DNA
sequence analysis of the ENG, ACVRL1, and SMAD4 genes
was carried out using a polymerase chain reaction (PCR) with
the primers designed by the authors. PCR was initially per-
formed using a thermal cycler (model 9600, Applied Biosys-
tems, Foster City, CA, U.S.A.), and DNA sequencing was car-
ried out using an ABI Prism 3100 Genetic Analyzer with a
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems).
Multiple ligation-dependent probe amplification (MLPA)
To identify the deletional mutations, MLPA was performed
following the directions provided by MRCHolland, Amster-
dam, The Netherlands (http://www.mlpa.com), using a probe
set for HHT (SALSA MLPA KIT P093 HHT/PPH1) cov-
ering 13 of the 14 exons of ENG (except for exon 12) and all
the 10 exons of ACVRL. MLPA was performed on the ABI
9700 thermocycler (Applied Biosystems). Amplicons were
separated on a capillary sequencer (ABI 3130 genetic analyz-
er, Applied Biosystems). Before separation, Genescan-ROX
500 (Applied Biosystems) was added to the samples to facili-
tate estimation of fragment sizes. Data analysis was performed
using the GeneScan (Applied Biosystems) and GeneMarker
(SoftGenetics, State College, PA, U.S.A.) software. Relative
peak area values obtained in the patients were compared to
those obtained in healthy controls and were expressed as ratios.




The Clinical features and mutations identified in the five
Korean patients were summarized in the Table 1. Patient 1
had recurrent epistaxis and pulmonary AVM along with focal
telangiectasia on the fingers (particularly the periungal regi-
ons), lips, and oral mucosa (Fig. 1A, B). A history of recur-
rent epistaxis was found in her father and 32-yr-old daugh-
ter (Fig. 2A). Computed tomography (CT) angiography of
the liver showed an enlarged celiac axis and a prominent hep-
atic artery with multiple aberrant collateral vessels. Hetero-
geneous attenuation of the liver was also noted (Fig. 3A, B). 
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*Novel mutations.
HHT, hereditary hemorrhagic telangiectasia; AVM, arteriovenous malformation; CNS, central nervous system; GI, gastrointestinal; PFO, patent
foramen ovale.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex/Age 51/F 42/M 41/F 52/F 21/F
Mutation ENG c.277C>T ENG c.992-1G>C ACVRL1 c.81dupT --
(p.Arg93X) (splicing defect)* (p. Arg28SerfsX10)*
Epistaxis grade (onset) Grade 2 Grade 1 Grade 2 Grade 2 Grade 2
(early fourty) (mid thirty) (mid thirty) (mid twenty) (early childhood)
Hemoglobin (g/dL) 11.0 14.2 6.0 9.2 13.8
Telangiectasia Yes Yes - Yes -
Pulmonary AVM Yes Yes Yes Yes Yes (extensive)
Cerebral AVM -- - - -
CNS involvement -- Yes (stroke) Yes (abscess) -
Hepatic AVM Yes - Yes - Yes
GI mucosal involvement -- - Unknown Unknown
Other features -- Varicose veins, PFO --
Family history Yes Yes Yes Yes No
Table 1. Clinical features and mutations identified in five Korean patients with HHTPatient 2 had pulmonary AVM and telelangiectasia was
found on his tongue, along with a history of frequent epistaxis.
Recurrent epistaxis histories were also found in his father, four
sisters, and eight-year-old son. His father was diagnosed with
HHT with recurrent massive epistaxis requiring frequent
blood transfusions, telangiectasia on the oral mucosa (Fig. 1C),
and pulmonary AVM. Pulmonary angiography of patient 2
revealed a large pulmonary AVM with an aneurysmal sac (Fig.
4A). Selective coil embolization of the feeder vessels of the
pulmonary AVM was performed and the hemoptysis subsided.
Patient 3 experienced a momentary seizure-like movement
and a sudden attack of aphasia. A history of frequent epistaxis
and chronic anemia was found. At the age of 17, she had a
pulmonary segmentectomy because of a pulmonary AVM.
She had a family history of recurrent epistaxis (the detailed
pedigree could not be obtained). Multiphase contrast-enhanced
CT of the brain revealed an occlusion of the left intracranial
artery at the middle cerebral artery (MCA) bifurcation level
with findings of an acute infarct. Abdominal CT revealed a
severe tortuous dilatation of the hepatic artery and its intra-
hepatic branches with mottled hepatic enhancement (Fig. 3C,
D). Chest CT and pulmonary angiography revealed a new
small-sized pulmonary AVM in the right middle lobe (Fig.
4B). A wedge resection was performed as a result. The trans-
esophageal echocardiogram revealed a patent foramen ovale. 
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Fig. 1. Clinical features of the HHT patients: (A) telangiectasia on the periungal regions of the fingers of patient 1, (B) telangiectasia on the
lips of patient 1, (C) telangiectasia on the oral mucosa of the father of patient 2, (D) bleeding foci in the Kisselbach’s plexus of patient 3;
(E) microtelangia on the tongue of patient 5, and (F) clubbing fingers with one small hemangioma in patient 5.
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BPatient 4, a 52-yr-old Korean female, was found to have a
mass in the right parietal lobe of the brain. She complained
of severe headache with fever, chill, nausea and vomiting. She
had neck stiffness and microtelangiectasia on the trunk. She
had a history of recurrent epistaxis and chronic anemia. There
was a family history of epistaxis in her uncle and daughter
(detailed pedigree could not be obtained), and her daughter
had died suddenly from a hemangioma one year before the
patient visited to our hospital. A brain pre- and post-contrast
CT showed a rim-enhancing mass in the right parieto-tem-
poral lobe suggesting an abscess with cavity formation. Pul-
monary angiography revealed multifocal AVM in both lungs
(Fig. 4C). Selective coil embolization of the AVM in the lung
was performed, followed by a craniotomy and abscess drainage
with the removal of the abscess wall.
Patient 5, a 21-yr-old Korean female, had severe dyspnea
and a pulmonary AVM. She had a history of cyanosis, dysp-
nea, and clubbing of her fingers at birth, as well as multiple
AVM in the lung. She underwent a segmentectomy of both
lungs at the age of nine. A visual inspection revealed an ac-
neiform eruption on her face, microtelangiectasia on the to-
ngue, and clubbing fingers with one small telangiectasia (Fig.
1E, F). The chest CT and pulmonary angiography revealed
extensive peripheral AVM in both lungs (Fig. 4D) and a prob-
able arterioportal shunt involving the liver. Selective coil em-
bolization of the AVM in the lung was performed twice, and
the dyspnea was ameliorated.
Mutation analysis
Direct sequencing of the ENG gene was performed initial-
ly for all the five patients with HHT. A nonsense mutation
producing a premature stop signal at codon 93 (c.277C>T;
p.Arg93X) in exon 3 of the ENG gene was found in patient
1, which has previously been reported in HHT-1 patients
(23). Patient 2 had a base substitution at a consensus splic-
ing acceptor site of the 9th intron of the ENG gene (c.992-
1G>C) predicting a splicing defect. This mutation has not
been reported previously. We additionally performed direct
sequencing of the ACVRL1 gene for three remaining patients
and found one patient with mutation; patient 3 had a novel
a frameshift mutation as a result of a duplication of one base
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Fig. 3. Radiology findings of the HHT patients. (A) and (B) CT angiography of the liver in patient 1 shows an enlarged celiac axis (arrow),
a prominent hepatic artery (arrowhead) with multiple aberrant collateral vessels, and heterogeneous attenuation of the liver. (C) and (D)
Abdominal CT of patient 3 shows severe tortuous dilatation of the hepatic artery (arrow) and its intrahepatic branches (arrowhead) with
mottled hepatic enhancement.
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C Dpair in the coding region (exon 2) of the ACVRL1 gene pro-
ducing a premature termination codon (c.81dupT; p.Arg28
SerfsX10) (Fig. 5). We could not perform further genetic anal-
ysis on the family members of the patients with mutation. 
Since patients 4 and 5 did not have any mutations in the
ENG and ACVRL1 genes, we additionally screened them
for the SMAD4 genes, but the results were negative. Subse-
quent MLPA analysis found no gross deletions in the ENG
or ACVRL1 genes in these two patients. Because the P093
HHT/PPH1 MLPA kit also covers the 13 exons of the BMPR2
gene, the causative gene for primary pulmonary hyperten-
sion which sometimes shares identical pulmonary manifes-
tations with HHT, we could get additional information on
this gene. The remaining two patients showed negative results
for the BMPR2 gene.
DISCUSSION
Table 1 gives a summary of the clinical features and results
of mutation analysis. All the five patients showed the typi-
cal manifestations of HHT with variable individual expres-
sion of the clinical features. The onset of epistaxis was rather
late in these cases (with the exception of patient 5) compared
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Fig. 4. Pulmonary angiography of the HHT patients. (A) a large pulmonary arteriovenous malformation (AVM) in patient 2; (B) a new small-
sized pulmonary AVM in the right middle lobe in patient 3; (C) multifocal AVM in patient 4; (D) extensive peripheral AVM in patient 5.
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C Dwith normal HHT patients, in whom most manifest recur-
rent epistaxis before the age of 20 (15, 24). Pulmonary
AVM was observed in all five patients, which is believed to
be somewhat unusual considering that only 15-30% of HHT
patients have pulmonary AVM (15, 25-27). This might be
due to the probable selection bias in this study in those patients
with severe clinical manifestations such as pulmonary AVM
are referred to our hospital for an evaluation of HHT. How-
ever, there remains a possibility that high prevalence of pul-
monary AVM might be a unique characteristic in Korean pa-
tients with HHT; our review of all the literatures addressing
Korean patients with HHT found that 13 out of 22 (-59%)
patients had pulmonary AVM (28). Further studies on a large
set of patients would be needed to clarify these issues, inves-
tigating genetic and environmental factors in Korean popu-
lations. Patient 5 had relatively severe clinical manifestations
such as infantile cyanosis resulting from a congenital pulmo-
nary AVM, which is quite unusual with very few cases (<30)
being reported thus far (27, 29). This might be because most
cases of congenital AVM are asymptomatic. This suggests that
there might be a specific genetic background in this patient.
Molecular analysis of the ENG, ACVRL1, and SMAD4
genes in the five Korean patients with HHT revealed three
individuals with mutations in either the ENG or ACVRL1
genes. Endoglin is a membrane protein of the disulphide-
linked homodimer that is expressed mainly in the endothe-
lial cells of all vessels. This molecule binds the transforming
growth factor-β(TGF-β ), which is a powerful mediator of
vascular remodeling induced by various stimuli such as vas-
cular wall stress, and forms a signaling heteromeric complex
(26, 30). The vast majority (-80%) of mutations of the ENG
gene identified in HHT-1 patients are premature stop codons
and truncated polypeptides, which appear to act as null alle-
les resulting in a haploinsufficiency (2). The mutation in pa-
tient 1 is a nonsense mutation located in the extracellular
domain of the endoglin molecule predicting truncated pro-
tein with loss of the transmembrane domain, while patient
2 had a splice site mutation at the highly conserved sequence
of the acceptor site of exon 7. Mutation analysis of the fami-
ly members could not be carried out due to the unavailabil-
ity of specimens. However, considering the obvious expec-
tation of the abnormal mutant products, those family mem-
bers with the typical features of HHT are believed to possess
the same mutations on the ENG gene. The activin A recep-
tor type II-like 1 encoded by ACVRL1 belongs to the TGF-β
superfamily receptor group, which signals through Smad1/5.
Moreover, this molecule is expressed almost exclusively in en-
dothelial cells, particularly during angiogenesis (31, 32). Pati-
ent 3 had a duplication mutation on exon 2 of the ACVRL1
gene, which is one of mutational hot spot and encodes part
of the extracellular domain, predicting a frameshift and very
short truncated protein removing the cystein rich (extracel-
lular), transmembrane, kinase, and intracellular domain. The
truncation mutations in patient 1 and 3 might fit into the
haplo-insufficiency model rather than the dominant-negative
model, because the mutant proteins lack the transmembrane
domain and they would have less chance to form a heterodimer
with normal protein.
There is significant phenotypic variability and genetic het-
erogeneity in HTT. Sequence analysis of the ENG and AC-
VRL1 genes reveals mutations in 60-80% of individuals with
HHT (33, 34). Several techniques including quantitative PCR,
MLPA and southern blot analysis can identify those deletions
undetectable by sequence analysis, which can increase the de-
tection rate by up to 10-20% (14, 35). However, mutation
analysis of the ENG and ACVRL1 genes can fail to detect
mutations in the remaining patients. This suggests the pos-
sibility of mutations in the non-coding regions of these genes
or mutations in other genes. Recently, linkage analysis in two
HHT families identified new HHT loci: HHT-3 in chromo-
some 5q31.3-32, and HHT-4 in chromosome 7p14 (19, 20).
It is possible that patients 4 and 5, who tested negative to
mutations in the ENG and ACVRL1 genes, might have muta-
tions in another unidentified gene. Gallione et al. (21) recent-
ly reported that mutations in the SMAD4 tumor suppressor
gene might be associated with a combined syndrome of JPHT.
Because some cases with SMAD4 mutations show clinical
manifestations of HHT without juvenile polyposis (36), we
screened mutations in the SMAD4 gene in patients 4 and 5,
and the results were negative.
HHT occurs with a wide ethnic and geographic distribu-
tion. The prevalence of HHT has been reported to range from
-1:1,300 to -1:40,000 depending on the geographic or eth-
nic region (2-9). Moreover, the type and frequency of specif-
ic mutations in different localities can vary widely with some
regions having a specific founder mutation. For example, a
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Fig. 5. Sequencing results of three mutation-positive patients with
HHT. (A) ENG c.277C>T (p.Arg93X) in patient 1; (B) ENG c.992-
1G>C (splicing defect) in patient 2; (C) ACVRL1 c.81dupT (p. Arg
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Cstudy in France and northern Italy revealed higher frequen-
cy (-2.7 times) of HHT-2 than HHT-1 (15). The prevalence
of HHT in the Korean population appears to be low with
only occasional cases being reported thus far. However, the
precise incidence, clinical characteristics, and genetic back-
ground of HHT in the Korean population are unknown be-
cause no epidemiological surveys have been carried out. Al-
though only a small number of patients were investigated,
this study indicates that there might be a specific clinical dif-
ference in Korean HHT patients. This highlights the need
for more studies on a large set of patients in this regional
population. Furthermore, more studies on the genetic back-
ground of Korean patients with HHT as well as the identi-
fication of another causative gene is needed. It is expected
that such studies will help us better understand this serious
but overlooked disorder and develop more appropriate ther-
apeutic strategies.
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